![Yury Kukushkin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yury Kukushkin
Director/Miembro de la Junta en Veralox Therapeutics, Inc. .
Cargos activos de Yury Kukushkin
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Veralox Therapeutics, Inc.
![]() Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Director/Miembro de la Junta | 01/12/2020 | - |
Code Biotherapeutics, Inc.
![]() Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Director/Miembro de la Junta | 01/03/2021 | - |
Hevolution Foundation | Corporate Officer/Principal | 01/09/2023 | - |
Historial de carrera de Yury Kukushkin
Antiguos cargos conocidos de Yury Kukushkin.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
4bio Capital Partners | Inversor de Capital Privado | 01/05/2016 | 01/09/2023 |
JDRF T1D Fund
![]() JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Inversor de Capital Privado | 01/09/2019 | 01/09/2023 |
Formación de Yury Kukushkin.
Moscow State University Lomonosov | Masters Business Admin |
Max Planck Institute of Biochemistry | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Alemania | 3 |
Rusia | 2 |
Operativa
Private Equity Investor | 2 |
Doctorate Degree | 2 |
Director/Board Member | 2 |
Sectorial
Consumer Services | 4 |
Finance | 3 |
Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
4bio Capital Partners | Finance |
JDRF T1D Fund
![]() JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Finance |
Veralox Therapeutics, Inc.
![]() Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
Code Biotherapeutics, Inc.
![]() Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
Hevolution Foundation |
- Bolsa de valores
- Insiders
- Yury Kukushkin
- Experiencia